Phase 2 Study of IDH305 in Subjects With IDH1 Mutant Grade II or III Glioma That Has Progressed After Observation or Radiation Therapy
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs IDH 305 (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 04 Aug 2017 Status changed from not yet recruiting to recruiting.
- 12 May 2017 Planned initiation date changed from 1 Jan 2017 to 1 Jul 2017.
- 02 Dec 2016 New trial record